IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1051-1075 out of 1275.

<< < 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 > >>

Public Release: 1-Oct-2014
Cancer Research
Immunotherapy could stop resistance to radiotherapy
Treating cancers with immunotherapy and radiotherapy at the same time could stop them from becoming resistant to treatment.
Cancer Research UK, MedImmune

Contact: Simon Shears
Cancer Research UK

Public Release: 1-Oct-2014
Journal of Interferon & Cytokine Research
A new target for controlling inflammation? Long non-coding RNAs fine-tune the immune system
Regulation of the human immune system's response to infection involves an elaborate network of complex signaling pathways that turn on and off multiple genes. The emerging importance of long noncoding RNAs and their ability to promote, fine-tune, and restrain the body's inflammatory response by regulating gene expression is described in a Review article in Journal of Interferon & Cytokine Research.

Contact: Kathryn Ryan
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 1-Oct-2014
Neurobiology of Disease
Medical discovery first step on path to new painkillers
A major medical discovery by scientists at the University of Nottingham could lead to the development of an entirely new type of painkiller.
Wellcome Trust, Diabetes UK, British Heart Foundation, Richard Bright VEGF Research Fund

Contact: Emma Thorne
University of Nottingham

Public Release: 1-Oct-2014
Science Signaling
Eighty percent of bowel cancers halted with existing medicines
An international team of scientists has shown that more than 80 percent of bowel cancers could be treated with existing drugs. The study found that medicines called 'JAK inhibitors' halted tumor growth in bowel cancers with a genetic mutation that is present in more than 80 per cent of bowel cancers. Multiple JAK inhibitors are currently used, or are in clinical trials, for diseases including rheumatoid arthritis, psoriasis, blood cancers and myeloproliferative disorders.
Ludwig Cancer Research, Australian National Health and Medical Research Council, Cancer Council Victoria, Royal Melbourne Hospital, Victorian Government

Contact: Alan Gill
Walter and Eliza Hall Institute

Public Release: 1-Oct-2014
ACS Nano
'Stealth' nanoparticles could improve cancer vaccines
Cancer vaccines have recently emerged as a promising approach for killing tumor cells before they spread. But so far, most clinical candidates haven't worked that well. Now, scientists have developed a new way to deliver vaccines that successfully stifled tumor growth when tested in laboratory mice. And the key, they report in the journal ACS Nano, is in the vaccine's unique stealthy nanoparticles.

Contact: Michael Bernstein
American Chemical Society

Public Release: 1-Oct-2014
Journal of Nuclear Medicine
FDG-PET/CT shows promise for breast cancer patients younger than 40
Researchers at Memorial Sloan Kettering found that PET/CT imaging of patients younger than 40 who were initially diagnosed with stage I-III breast cancer resulted in change of diagnosis. As reported in the October issue of The Journal of Nuclear Medicine, while guidelines recommend FDG-PET/CT imaging only for women with stage III breast cancer, it can also help physicians more accurately diagnose young breast cancer patients initially diagnosed with earlier stages of the disease.

Contact: Kimberly Brown
Society of Nuclear Medicine

Public Release: 30-Sep-2014
Health Technology Assessment
Genetic test would help 'cut bowel cancer spread'
Screening families of patients with bowel cancer for a genetic condition would cut their risk of developing bowel, womb, and ovarian cancers, new research has found.
National Institute for Health Research

Contact: Chris Jones
Cardiff University

Public Release: 30-Sep-2014
British Journal of Cancer
Targeted treatment could halt womb cancer growth
A drug which targets a key gene fault could halt an aggressive womb cancer and shrink tumours, according to research published in the British Journal of Cancer.

Contact: Emily Head
Cancer Research UK

Public Release: 30-Sep-2014
First mapping that reveals the molecular pathway for MDSC cancer progression
InSilico Medicine and partners establish a map for cancer progression induced by MDSCs, and a means to extinguish them.
Federal Clinical Research Center of Pediatric Hematology, Oncology and Immunology

Contact: Michael Petr
InSilico Medicine, Inc.

Public Release: 30-Sep-2014
Medical professional liability claims and esophageal cancer screening
An analysis of liability claims related to esophageal cancer screening finds that the risks of claims arising from acts of commission -- complications from screening procedure -- as well as acts of omission -- failure to screen -- are similarly low, according to a study in the Oct. 1 issue of JAMA.

Contact: Shantell Kirkendoll
The JAMA Network Journals

Public Release: 30-Sep-2014
Angewandte Chemie International Edition
Cancer therapy: Driving cancer cells to suicide
Researchers of Ludwig-Maximilians-Universitaet in Munich report that a new class of chemical compounds makes cancer cells more sensitive to chemotherapeutic drugs. They have also pinpointed the relevant target enzyme, thus identifying a new target for anti-tumor agents.

Contact: Luise Dirscherl
Ludwig-Maximilians-Universität München

Public Release: 30-Sep-2014
Journal of General Internal Medicine
Endoscopists recommend frequent colonoscopies, leading to its overuse
A retrospective study led by researchers at Brigham and Women's Hospital, has found an overuse of colonoscopies for colorectal cancer screening and surveillance. The study demonstrated that endoscopists commonly recommended shorter follow-up intervals than established guidelines support, and these recommendations were strongly correlated with subsequent colonoscopy overuse.
NIH/National Cancer Institute

Contact: Marjorie Montemayor-Quellenberg
Brigham and Women's Hospital

Public Release: 30-Sep-2014
Proceedings of the National Academy of Sciences
New discovery approach accelerates identification of potential cancer treatments
Researchers at the University of Michigan have described a new approach to discovering potential cancer treatments that requires a fraction of the time needed for more traditional methods.
Life Sciences Institute's Innovation Partnership

Contact: Laura Williams
University of Michigan

Public Release: 30-Sep-2014
FASEB Journal
New blood test determines whether you have or are likely to get cancer
A new research report published in the October 2014 issue of the FASEB Journal may make early detection and the risk assessment of cancer as easy as a simple blood test.

Contact: Cody Mooneyhan
Federation of American Societies for Experimental Biology

Public Release: 30-Sep-2014
New guidelines for treatment of hypothyroidism endorse current therapy
Levothyroxine is considered the gold standard therapy for an underactive thyroid gland, and a new review of therapies for the condition -- including combining levothyroxine with another agent -- has not altered that assessment, say a team of investigators.Their analysis, published as a set of guidelines in the journal Thyroid (available free online), finds insufficient consistent data exist to recommend a change in use of levothyroxine -- whether generic, or sold under various trade names, such as Synthroid -- as the only drug needed to treat hypothyroidism.
National Institutes of Health

Contact: Karen Teber
Georgetown University Medical Center

Public Release: 30-Sep-2014
Health Technology Assessment
Genetic test for cancer patients could be cost-effective and prevent further cases
Screening for a genetic condition in younger people who are diagnosed with bowel cancer would be cost-effective for the British National Health Service and prevent new cases in them and their relatives, new research has concluded.
National Institute for Health UK

Contact: Louise Vennells
University of Exeter

Public Release: 30-Sep-2014
New hypothyroidism treatment guidelines from American Thyroid Association
Levothyroxine (L-T4), long the standard of care for treating hypothyroidism, is effective in most patients, but some individuals do not regain optimal health on L-T4 monotherapy. An expert task force of the American Thyroid Association on thyroid hormone replacement reviewed the latest studies on L-T4 therapy and on alternative treatments to determine whether a change to the current standard of care is appropriate, and they present their recommendations in an article published in Thyroid.

Contact: Kathryn Ryan
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 30-Sep-2014
2014 IEEE International Ultrasonics Symposium
'Virtual breast' could improve cancer detection
Scientists have developed a 'virtual breast' to help train clinicians in the use of ultrasound elastography. The advanced imaging technique holds promise for improving cancer detection, but only if the results are interpreted properly.
National Cancer Institute

Contact: Jennifer Donovan
Michigan Technological University

Public Release: 30-Sep-2014
New England Journal of Medicine
NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer
In this multi-center study of 50 patients with advanced non-small cell lung cancer testing positive for ROS1 gene rearrangement, the response rate was 72 percent, with 3 complete responses and 33 partial responses. Median progression-free survival was 19.2 months.
NIH/National Cancer Institute

Contact: Garth Sundem
University of Colorado Denver

Public Release: 30-Sep-2014
Journal of General Internal Medicine
Americans undergo colonoscopies too often, study finds
Colonoscopies are a very valuable procedure by which to screen for the presence of colorectal cancer. However, it seems that healthy Americans who do undergo this sometimes uncomfortable examination often have repeat screenings long before they actually should. Gina Kruse of Massachusetts General Hospital in the US and colleagues advise that endoscopists stick to the national guidelines more closely. Their findings appear in the Journal of General Internal Medicine, published by Springer.
National Cancer Institute, Health Resources and Services Administration, Ryoichi Sasakawa Fellowship Fund

Contact: Joan Robinson

Public Release: 29-Sep-2014
ESMO 2014 Congress
Trial shows trastuzumab should remain as standard of care for HER2-positive breast cancer
Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab, also known as Herceptin, should remain the standard of care for this cancer, says a Mayo Clinic researcher.
Breast Cancer Intergroup of North America, Breast International Group, NIH/National Cancer Institute, Glaxo SmithKline

Contact: Paul Scotti
Mayo Clinic

Public Release: 29-Sep-2014
Nature Methods
Experts from CNIO discover shining cells responsible for developing tumors
Researchers from the Spanish National Cancer Research Centre have discovered and characterized a new specific marker for cancer stem cells: riboflavin, or vitamin B2, a pigment that emits green fluorescence as a result of its accumulation inside intracellular vesicles. This light emission property, acts to track, isolate, and later purify it, without the need for antibodies or other more costly and complex techniques.

Contact: Nuria Noriega
Centro Nacional de Investigaciones Oncologicas (CNIO)

Public Release: 29-Sep-2014
Journal of Agricultural and Food Chemistry
New way to detox? 'Gold of Pleasure' oilseed boosts liver detoxification enzymes
University of Illinois scientists have found compounds that boost liver detoxification enzymes nearly fivefold, and they've found them in a pretty unlikely place -- the crushed seeds left after oil extraction from an oilseed crop used in jet fuel.
US Department of Agriculture

Contact: Phyllis Picklesimer
University of Illinois College of Agricultural, Consumer and Environmental Sciences

Public Release: 29-Sep-2014
Molecular Cancer Therapeutics
Transplant drug could boost the power of brain tumor treatments, U-M study finds
Every day, organ transplant patients around the world take a drug called rapamycin to keep their immune systems from rejecting their new kidneys and hearts. New research suggests that the same drug could help brain tumor patients by boosting the effect of new immune-based therapies.
National Institutes of Health, University of Michigan, Phase One Foundation

Contact: Kara Gavin
University of Michigan Health System

Public Release: 29-Sep-2014
Genetic modifier affects colon tumor formation
Kristi Neufeld studies the adenomatous polyposis coli protein, which protects against colon cancer. Many of her experiments involve testing mice with APC mutations, which cause colon cancer, and seeing if any new drug compounds will work against the mutations.

Contact: Brendan M. Lynch
University of Kansas

Showing releases 1051-1075 out of 1275.

<< < 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 > >>

  Search News Releases